“The advancement of novel therapies like CAR-T in relapsed and refractory pediatric B-ALL is truly a beacon of hope for children and young adults with a previously dismal prognosis.”
Credit: 2024 Hoover.
“The advancement of novel therapies like CAR-T in relapsed and refractory pediatric B-ALL is truly a beacon of hope for children and young adults with a previously dismal prognosis.”
BUFFALO, NY- May 17, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “The price of hope: CAR-T therapy in pediatric leukemia.”
We stand at the crossroads of medical innovation, where cutting-edge scientific discoveries intersect with the resilience of the human body, providing hope to families grappling with a diagnosis of pediatric leukemia. In this new editorial, researcher Alex Hoover from the University of Minnesota Medical School’s Division of Pediatric Blood and Marrow Transplantation discusses the chimeric antigen receptor T-cell (CAR-T) therapy tisagenlecleucel (tisa-cel) — a groundbreaking development in the treatment of B-cell lineage acute lymphoblastic leukemia (B-ALL) (the most common childhood cancer).
Following the pivotal ELIANA trial, tisa-cel was approved in the United States for the treatment of refractory or second or greater relapse of B-ALL in patients under age 25 [1, 2]. This innovative therapy involves genetically modifying a patient’s native T-cells – immune cells with the ability to kill and/or regulate infected or diseased cells – to express a receptor that targets cancer cells. The tisa-cel product is specifically engineered to target CD19 on B-lineage cells and has shown promising results in a historically challenging relapsed and refractory population.
Upon its approval in 2017, Novartis priced tisa-cel at $475,000 – a number that many healthcare systems and payers balked at initially – and in 2023 the price increased to $508,250. However, compared to more recently approved ex vivo gene therapies such as bluebird bio’s Zynteglo for beta thalassemia priced at $2.8 million or Vertex Pharmaceuticals’ Casgevy for sickle cell disease at $2.2 million, the half-million dollar tisa-cel price tag is less staggering. Importantly, the listed cost of these therapies includes only the product and does not include the healthcare cost for other necessary care including leukapheresis, chemotherapy administration and adverse event monitoring and management.
“Our team recently published an in-depth analysis of the comprehensive cost and utilization of commercial CAR-T therapy in pediatric B-ALL patients with commercial insurance in the United States [3].”
Continue reading: DOI: https://doi.org/10.18632/oncoscience.598
Correspondence to: Alex Hoover
Email: hoove231@umn.edu
Keywords: CAR-T, cost, pediatric leukemia
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4
###
Journal
Oncoscience
Method of Research
Commentary/editorial
Subject of Research
People
Article Title
The price of hope: CAR-T therapy in pediatric leukemia
Article Publication Date
25-Apr-2024
